TABLE 3.
Drug treatment of patients with Wilson's disease
| Pre‐1959 | 1960–1969 | 1970–1979 | 1980–1989 | 1990–1999 | 2000–2009 | 2010–2019 | p value for cross‐decade comparisons | |
|---|---|---|---|---|---|---|---|---|
| DP treatment at diagnosis, n (%) | 15 (71.4) | 42 (77.8) | 64 (91.4) | 55 (82.1) | 101 (58.0) | 158 (50.2) | 105 (46.1) | <0.001 |
| Zinc treatment at diagnosis, n (%) | 0 (0.0) | 1 (1.9) | 4 (5.7) | 12 (17.9) | 79 (45.4) | 147 (46.7) | 116 (50.9) | <0.001 |
| Switch from zinc to DP, n (%) | 0 | 0 | 0 | 3 (4.5) | 11 (6.3) | 23 (7.3) | 11 (4.8) | <0.001 |
| Switch from DP to zinc, n (%) | 0 | 0 | 2 (2.9) | 2 (3.0) | 6 (3.4) | 24 (7.6) | 16 (7.0) | <0.001 |
| Self‐reported compliance, n (%) | 0 (0.0) | 1 (25.0) | 15 (65.2) | 13 (48.1) | 56 (54.4) | 148 (54.8) | 173 (82.0) | <0.001 |
Abbreviation: DP, D‐penicillamine.